**Supplementary Figure 1: Scatter plots of AGR2, SYCN and REG1B in the training and validation cohorts**

AGR2 (A,B), REG1B (C,D) and SYCN (E,F) for training and validation cohorts respectively. Black horizontal lines represent the medians. PDAC=pancreatic ductal adenocarcinoma.

**Supplementary Figure 2: Diagnostic performances of CA19.9, CA125, LAMC2, AGR2, SYCN and REG1B for all PDAC patients versus healthy controls as individual markers**

Receiver operator characteristics (ROC) curves for CA19.9, CA125, LAMC2, AGR2, SYCN and REG1B for all patients with pancreatic ductal adenocarcinoma (PDAC) versus all healthy controls as individual markers in the training cohort (A) and validation cohort (B). The area under the curve (AUC) for each marker is provided along with its associated 95% confidence intervals in brackets.

**Supplementary Figure 3: Complementarity of CA19.9, CA125 and LAMC2 in differentiating all PDAC patients versus healthy controls**

Receiver operator characteristics (ROC) curves for CA19.9, CA125+CA19.9, CA19.9+LAMC2 and CA125+CA19.9+LAMC2 multiple markers models for all patients with pancreatic ductal adenocarcinoma (PDAC) versus healthy controls in the training (A) and validation cohort (B). The area under the curve (AUC) for each marker is provided along with its associated 95% confidence intervals in brackets.

**Supplementary Figure 4. Correlation plot of log10 CA125 and log10 CUZD1 with the linear trend line and equation.**